



Company and PT-112 Overview

**Why should
Promontory
Therapeutics
be the
Prix Galien
Start-up of the
Year for 2023?**

Our focus on biology is yielding results

- PT-112 has demonstrable immunotherapy properties: within a small-molecule
- This is an innovative approach that could change immuno-oncology
- These properties have now been shown by the National Cancer Institute (NCI) to be valid in cancer patients (emerging proof of mechanism)
- This is driven by immunogenic cancer cell death (ICD), which is applicable across a broad number of solid and liquid tumors

Building upon successes created by others, and solving for gaps and limitations

- Because PT-112's MoA inhibits a fundamental driver of cancer cell biology (uncontrolled ribosomal biogenesis), it is widely applicable
- By addressing the cancer cell in an immunogenic manner, PT-112 can overcome the limitations of T cell-directed approaches
- This approach is distinct from and complementary to such modalities, with a focus on immune activation
- "Immune cold" tumors, such as prostate cancer, can benefit from this approach

We are changing the paradigm of biotech development of new medicines, with capital efficient and lean operations

- We are an independent company, funded by global family investment offices
- Successfully advancing a lead clinical candidate into three Phase 2 studies, with total invested capital of \$74MM

A person in a light-colored jacket and dark pants stands on a jagged, mossy rock peak. The background shows a calm body of water and a distant shoreline under a hazy sky.

MISSION

**To be the leading company deploying
immunogenic small molecules
to markedly improve treatment outcomes
for cancer patients worldwide**



A pioneer in small molecule immunotherapy approaches

Novel mechanism of lead agent, PT-112

- Overcomes limitations of current T cell directed I-O approaches
- Inhibits *ribosomal biogenesis*, selectively killing cancer cells
- Leads to the induction of *immunogenic cell death (ICD)*, creating an effective and durable anti-tumor immune response
- Targets both soft tissue and bone sites of disease
- Applies across solid and liquid tumors

PT-112 is a mid-stage, clinical-stage asset targeting underserved populations with high unmet need

- Metastatic castrate-resistant prostate cancer (mCRPC)
- Non-small cell lung cancer (NSCLC)
- Thymic epithelial tumors (TETs)
- Hematological malignancies

Robust pre-clinical and clinical data package

- Completed three Phase I studies
- Advancing three Phase II programs
- Demonstrated safety, efficacy, and durability as monotherapy and in combination
- Top-tier clinical leadership in US and Europe
- National Cancer Institute (NCI) fully sponsoring an indication through Phase 2
- Clinical evidence of immune activation by PT-112 monotherapy

Strong global IP portfolio through 2039 and beyond

Experienced management team, board, and clinical advisors